2-氯-4-甲基-5-氟吡啶 | 881891-83-4

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-氯-4-甲基-5-氟吡啶
• 中文别名: 2-氯-5-氟-4-甲基吡啶
• 英文名称: 2-chloro-5-fluoro-4-methylpyridine
• CAS: 881891-83-4
• 化学式: C₆H₅ClFN
• mdl: MFCD09864695
• 分子量: 145.564
• InChiKey: HWDRAVIZSYVICK-UHFFFAOYSA-N

物化性质

• 沸点：
  183℃
• 密度：
  1.264
• 闪点：
  64℃

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险品标志：
  T
• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

反应信息

• 作为反应物：
  描述：

  2-氯-4-甲基-5-氟吡啶 在 四(三苯基膦)钯 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.08h， 生成 5-{7-[bis-(4-methoxy-benzyl)-amino]-3-methyl-3H-benzoimidazol-5-yloxy}-4-methyl-pyridine-2-carbonitrile
  参考文献：
  名称：

  Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

  摘要：

  本发明公开了根据式I的化合物：其中Cy、R1、L1、R3、R4、R5、La和Ra如本文所定义。根据式I公开了新的苯并咪唑，能够抑制JAK，这些化合物可以制备为药物组合物，并可用于预防和治疗哺乳动物包括人类的各种疾病，包括但不限于过敏性疾病、炎症性疾病、自身免疫性疾病、增殖性疾病、移植排斥、涉及软骨周转障碍的疾病、先天软骨畸形以及与IL6过度分泌或干扰素过度分泌有关的疾病。

  公开号：

  US09440929B2

文献信息

• [EN] PYRIDINE DERIVATIVES AND THEIR USE AS MEDICAMENTS FOR TREATING DISEASES RELATED TO MCH RECEPTOR<br/>[FR] DERIVES DE PYRIDINE ET LEUR UTILISATION EN TANT QUE MEDICAMENTS POUR LE TRAITEMENT DES MALADIES LIEES AUX RECEPTEURS MCH
  申请人：TAISHO PHARMA CO LTD

  公开号：WO2006035967A1

  公开（公告）日：2006-04-06

  The present invention encompasses novel substituted pyridine compounds of Formula (I), which act as MCH receptor antagonists. These compositions and pharmaceutical compositions thereof are useful in the prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

  本发明涵盖了化学式（I）的新型取代吡啶化合物，其作为MCH受体拮抗剂。这些组合物及其药物组合物在预防或治疗改善记忆功能、睡眠和觉醒、焦虑、抑郁、情绪障碍、癫痫、肥胖、糖尿病、食欲和进食障碍、心血管疾病、高血压、血脂异常、心肌梗死、暴饮暴食障碍包括暴食症、厌食症、精神障碍包括躁郁症、精神分裂症、谵妄、痴呆、压力、认知障碍、注意力缺陷障碍、物质滥用障碍和运动障碍包括帕金森病、癫痫和成瘾症方面具有用处。
• NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS
  申请人：MENET Christel Jeanne Marie

  公开号：US20150203455A1

  公开（公告）日：2015-07-23

  The present invention discloses compounds according to Formula I: wherein Cy, R 1 , L 1 , R 3 , R 4 , R 5 , L a , and R a are as defined herein. Novel benzimidazoles according to Formula I, able to inhibit JAK are disclosed, these compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic diseases, inflammatory diseases, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or hypersecretion of interferons.

  本发明公开了根据以下公式I的化合物：其中Cy、R1、L1、R3、R4、R5、La和Ra如本文所定义。根据公式I的新型苯并咪唑，能够抑制JAK，这些化合物可以制备为药物组合物，并可用于预防和治疗包括人类在内的哺乳动物的各种疾病，包括但不限于过敏性疾病、炎症性疾病、自身免疫性疾病、增殖性疾病、移植排斥反应、涉及软骨周转障碍的疾病、先天性软骨畸形以及与IL6过度分泌或干扰素过度分泌相关的疾病。
• [EN] BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS<br/>[FR] DÉRIVÉS DE BENZIMIDAZOLE ET COMPOSITIONS PHARMACEUTIQUES DE CEUX-CI POUR LE TRAITEMENT DE TROUBLES INFLAMMATOIRES
  申请人：GALAPAGOS NV

  公开号：WO2015110378A1

  公开（公告）日：2015-07-30

  The present invention discloses compounds according to Formula (I) wherein Cy, R1, L1 R3, R4, R5, La, and Ra are as defined herein. Novel benzimidazoles according to Formula (I), able to inhibit JAK are disclosed, these compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic diseases, inflammatory diseases, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or hypersecretion of interferons.

  本发明公开了根据式(I)的化合物，其中Cy、R1、L1、R3、R4、R5、La和Ra如本文所定义。公开了根据式(I)的能够抑制JAK的新型苯并咪唑类化合物，这些化合物可以制备成药物组合物，并可用于预防和治疗包括人类在内的哺乳动物的各种疾病，包括但不限于过敏性疾病、炎症性疾病、自身免疫性疾病、增生性疾病、移植排斥、涉及软骨代谢障碍的疾病、先天性软骨畸形以及与IL6或干扰素过度分泌相关的疾病。
• [EN] PYRIDYL SUBSTITUTED INDOLE COMPOUNDS<br/>[FR] COMPOSÉS INDOLE SUBSTITUÉS PAR PYRIDYLE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2018049089A1

  公开（公告）日：2018-03-15

  Disclosed are compounds of Formula (I) N-oxide, or salt thereof, wherein R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

  揭示了Formula (I) N-oxide的化合物或其盐，其中R1、R2、R3、R4、R5、m、n和p在此处被定义。还揭示了使用这些化合物作为Toll样受体7、8或9信号抑制剂的方法，以及包含这些化合物的药物组合物。这些化合物在治疗炎症性和自身免疫性疾病方面非常有用。
• [EN] HETEROCYCLIC COMPOUNDS AS DIHYDROOROTATE DEHYDROGENASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE LA DIHYDROOROTATE DÉSHYDROGÉNASE
  申请人：JANSSEN BIOTECH INC

  公开号：WO2021156787A1

  公开（公告）日：2021-08-12

  Disclosed are compounds, compositions and methods for treating diseases, disorders, or medical conditions that are affected by the modulation of DHODH. Embodiments of such compounds are represented by Formula (I) and Formula (II) as follows: and wherein R1, R2, R3, R4, R5, R6, R7, R8, X1, X2, X3, X4, Y and Z, are defined herein.

  本文披露了一种通过调节DHODH来治疗受影响的疾病、紊乱或医疗状况的化合物、组合物和方法。这些化合物的实施例由以下的化学式(I)和化学式(II)表示：其中R1、R2、R3、R4、R5、R6、R7、R8、X1、X2、X3、X4、Y和Z在此定义。